Although other mTOR inhibitors (e.g., temsirolimus, deforolimus, tacrolimus, CC-223) have stepped into clinical trials for a variety of uses including cancer treatment (NCT00777959, NCT00483262) and immunosuppression (NCT00619398, NCT0093 1255), it has yet to be tested against a broad spectrum of IR injury (http://clinicaltrials.gov). Here, MTOR is linked to cancer.